Post first-line dacarbazine or temozolomide in neuroendocrine carcinoma - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Endocrine Connections Année : 2020

Post first-line dacarbazine or temozolomide in neuroendocrine carcinoma

Résumé

Objective: First-line chemotherapy in metastatic neuroendocrine carcinomas (NECs) is based on etoposide and platinum. However, there is no standard concerning second-line treatment. The objective of this study was to evaluate efficacy and tolerance of dacarbazine or temozolomide in metastatic digestive NEC as post first-line treatment. Material and methods: This study included patients with a metastatic NEC of digestive or unknown primary site. All patients received platinum-etoposide as first-line chemotherapy. Primary endpoint was progression-free survival (PFS). Secondary endpoints were clinical/morphological responses, toxicity, and overall survival (OS). Results: Twenty-seven patients were included: 17 received dacarbazine and 10 temozolomide as post-first line treatments. Median PFS was 3.0 (95%CI (2.2;3.7)) months. There was no significant difference between dacarbazine and temozolomide on PFS. Clinical and morphological responses were found in 12 and 9 patients, respectively. Median OS was 7.2 (95%CI (2.2;12.2)) months. The toxicity profile was that expected with such treatments. Conclusion: LV5FU2-dacarbazine or temozolomide-capecitabine chemotherapies allow a temporary clinical response for almost half of patients and/or a morphological response for a third of patients.
Fichier principal
Vignette du fichier
ec-EC-20-0192.pdf (670.12 Ko) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-04492751 , version 1 (21-05-2024)

Licence

Paternité - Pas d'utilisation commerciale - Pas de modification

Identifiants

Citer

Thomas Couronne, Paul Girot, Julien Hadoux, Thierry Lecomte, Alice Durand, et al.. Post first-line dacarbazine or temozolomide in neuroendocrine carcinoma. Endocrine Connections, 2020, 9 (6), pp.498-505. ⟨10.1530/ec-20-0192⟩. ⟨hal-04492751⟩
7 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More